F8 and hemophilia A: The objective of the present study was to develop a novel FVIII-peptide formulation with improved targeting to two immune inhibitory receptors, Siglec-3 and Siglec-9 on DCs to be employed as reverse vaccines for hemophilia A patients with inhibitory FVIII antibodies.